but the rates of platelet and red-cell transfusions were similar in the two groups (Table 2). We conducted a trial comparing two inhibitors of platelet glycoprotein IIb/IIIa, a group of agents ...

All of the trials currently available looked at the glycoprotein (GP) IIb/IIIa inhibitors in conjunction with heparin, in line with their licensed indications. There is an ongoing trial (A-Z trial) ...

4, 2003 (Vienna) -- Tirofiban, a glycoprotein IIb/IIIa inhibitor, initiated during transport ... associated with a "significantly higher TIMI 2 or 3 at initial angiography." The results are ...

Researchers at Demokritus University of Thrace, Institute of Applied Biosciences Centre for Research and Technology Hellas, National Hellenic Research Foundation and University of Athens have ...

Information from a large database supported the use of GP IIb/IIIa-receptor inhibitors in patients with AMI undergoing PCI. Treatment with abciximab was associated with favorable differences in ...

Glycoprotein IIb/IIIa inhibitors were administered in 129 patients (7.2%) who were assigned to bivalirudin ... events (Panel A), major bleeding (Panel B), major adverse cardiovascular events ...

Antibodies against β-2-glycoprotein I (β-2-GPI) play a crucial role in thrombus formation in conditions such as antiphospholipid syndrome (APS). Despite the efficacy of recombinant tissue plasminogen ...

The new findings, reported in the journal Science, could guide the development of more efficient inhibitors ... about P-glycoprotein, said Hassane Mchaourab, Ph.D., Louise B.

The transmembrane spike (S) glycoprotein on the SARS-CoV ... of the SARS-CoV-2 wild-type (WT) and five variants, namely B.1.351, B.1.1.7, P.1, B.1.617.2, and B.1.1.529. The study results indicate ...

It is recommended that a glycoprotein (GP) IIb/IIIa inhibitor is considered as an adjunct to percutaneous coronary intervention (PCI) for all patients with diabetes undergoing elective PCI, and for ...